Cubist Systematic Strategies’s VistaGen Therapeutics VTGN Stock Holding History

Cubist Systematic Strategies’s Portfolio VTGN Stock Details VTGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	$156K	Buy	+43,953	New	+$131K	﹤0.01%	2709
2025 Q2	–	Sell	-10,088	Closed	-$25.2K	–	3567
2025 Q1	$25.2K	Buy	+10,088	New	+$28.6K	﹤0.01%	2734
2023 Q3	–	Sell	-41,363	Closed	-$77.3K	–	3966
2023 Q2	$77.3K	Buy	+41,363	New	+$145K	﹤0.01%	3042
2022 Q4	–	Hold	0	–	–	–	4625
2022 Q3	–	Sell	-950	Closed	-$9.42K	–	4753
2022 Q2	$25K	Buy	950 +180	+23%	+$6.36K	﹤0.01%	4190
2022 Q1	$29K	Buy	+770	New	+$33.6K	﹤0.01%	3446
2021 Q4	–	Sell	-493	Closed	-$41K	–	3655
2021 Q3	$41K	Sell	493 -2,862	-85%	-$249K	﹤0.01%	2853
2021 Q2	$317K	Buy	3,355 +79	+2%	+$5.85K	﹤0.01%	2293
2021 Q1	$209K	Buy	3,276 +2,620	+399%	+$175K	﹤0.01%	2446
2020 Q4	$38K	Buy	+656	New	+$16.7K	﹤0.01%	2484

Other funds holding VTGN

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

TCM

TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return

Stempoint Capital New York $522M AUM 281.95% 1-Year Est. Return

NCM

Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return

Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return

SCM

Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Cubist Systematic Strategies's VTGN Position: Q3 2025 in Review

Cubist Systematic Strategies opened a new position in VistaGen Therapeutics (VTGN) in Q3 2025: 43,953 shares worth $156K. The stake represents ﹤0.01% of the portfolio and ranks #2709 among its holdings. This is a return to the name: Cubist Systematic Strategies previously reported a position in VTGN as recently as Q1 2025.

Cubist Systematic Strategies first reported a position in VTGN in Q4 2020 and has held it in 9 quarters since. The position peaked at $317K in Q2 2021. 58 funds tracked by Wall St. Rank hold VTGN as of Q3 2025.

Cubist Systematic Strategies held 43,953 shares of VistaGen Therapeutics worth $156K as of Q3 2025.
VistaGen Therapeutics was a new Cubist Systematic Strategies position in Q3 2025.
VistaGen Therapeutics made up ﹤0.01% of Cubist Systematic Strategies's portfolio in Q3 2025, its #2709 holding.
Cubist Systematic Strategies first reported a position in VistaGen Therapeutics in Q4 2020 and has held it in 9 quarters since.
Cubist Systematic Strategies's VistaGen Therapeutics position peaked at $317K in Q2 2021.
58 funds tracked by Wall St. Rank held VistaGen Therapeutics as of Q3 2025.

Based on Cubist Systematic Strategies's 13F filing for Q3 2025, filed 14 Nov 2025.